Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 · New England Journal of Medicine · 12K citations
https://doi.org/10.1056/nejmoa1504720
J
John M. Lachin
Milken Institute(US)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
520
Papers
56.7K
Citations
101
h-index
289
i10-index
John M. Lachin is an academic researcher from Milken Institute. The author has contributed to research in topics: Diabetes Management and Research & Diabetes Treatment and Management & Statistical Methods in Clinical Trials. The author has an h-index of 101, co-authored 442 publications.
ORCID: 0000-0001-9838-2841Papers by this author
worksEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 · New England Journal of Medicine · 3,565 citations
https://doi.org/10.1056/nejmoa1515920
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
2015 · New England Journal of Medicine · 2,543 citations
https://doi.org/10.1056/nejmoa1501352
Association Between 7 Years of Intensive Treatment of Type 1 Diabetes and Long-term Mortality
2015 · JAMA · 434 citations
https://doi.org/10.1001/jama.2014.16107
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014 · Cardiovascular Diabetology · 247 citations
https://doi.org/10.1186/1475-2840-13-102
A review of methods for futility stopping based on conditional power
2005 · Statistics in Medicine · 229 citations
https://doi.org/10.1002/sim.2151
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat